1. Report on influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza during 2022.
- Author
-
Diefenbach-Elstob TR, Chanthalavanh P, Bobbitt ME, Brown SK, Rynehart C, Spirason N, Peck H, Deng YM, Dapat C, Subbarao K, and Barr IG
- Subjects
- Animals, Female, Humans, Australia epidemiology, Chickens, Drug Resistance, Viral genetics, Drug Resistance, Viral immunology, Influenza A Virus, H1N1 Subtype genetics, Influenza A Virus, H3N2 Subtype genetics, Oseltamivir pharmacology, World Health Organization, Zanamivir pharmacology, Antiviral Agents pharmacology, Influenza A virus drug effects, Influenza A virus genetics, Influenza A virus immunology, Influenza Vaccines genetics, Influenza Vaccines immunology, Influenza Vaccines therapeutic use, Influenza, Human epidemiology, Influenza, Human genetics, Influenza, Human immunology, Influenza, Human prevention & control
- Abstract
As part of its role in the World Health Organization's (WHO) Global Influenza Surveillance and Response System (GISRS), the WHO Collaborating Centre for Reference and Research on Influenza in Melbourne received a record total of 12,073 human influenza positive samples during 2022. Viruses were analysed for their antigenic, genetic and antiviral susceptibility properties. Selected viruses were propagated in qualified cells or embryonated hen's eggs for potential use in seasonal influenza virus vaccines. In 2022, influenza A(H3N2) viruses predominated over influenza A(H1N1)pdm09 and B viruses, accounting for 77% of all viruses analysed. The majority of A(H1N1)pdm09, A(H3N2) and influenza B viruses analysed at the Centre were found to be antigenically and genetically similar to the respective WHO recommended vaccine strains for the southern hemisphere in 2022. Of 3,372 samples tested for susceptibility to the neuraminidase inhibitors oseltamivir and zanamivir, two A(H1N1)pdm09 viruses showed highly reduced inhibition against oseltamivir., (© Commonwealth of Australia CC BY-NC-ND)
- Published
- 2023
- Full Text
- View/download PDF